MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-06-2023
Aridis Pharmaceuticals Operating Cycle 2011-2026 | ARDS
Annual Operating Cycle Aridis Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 59 | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 59 | 59 | 59 |
Quarterly Operating Cycle Aridis Pharmaceuticals
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 155 | - | 114 | 156 | - | - | 88.6 | - | - | - | - | - | - | - | - | - | 74.1 | - | 148 | 6.89 K | 235 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.89 K | 74.1 | 982 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
115 | $ 20.52 | -2.12 % | $ 2.59 B |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Axsome Therapeutics
AXSM
|
273 | $ 164.13 | 0.15 % | $ 8.17 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
360 | $ 2.49 | -3.11 % | $ 15.6 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
285 | $ 64.24 | -3.37 % | $ 12.3 B | USA |
 |
BioCardia
BCDA
|
101 | $ 1.37 | 6.2 % | $ 29 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
947 | $ 8.61 | -1.66 % | $ 1.78 B | USA |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
408 | $ 11.47 | -0.43 % | $ 742 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Biogen
BIIB
|
402 | $ 187.68 | -2.16 % | $ 27.5 B | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
733 | $ 60.68 | -1.7 % | $ 11.6 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
153 | $ 62.54 | 0.27 % | $ 127 B | USA |
 |
Benitec Biopharma
BNTC
|
141 | $ 10.85 | -0.5 % | $ 447 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | Canada |
 |
BioXcel Therapeutics
BTAI
|
244 | $ 1.63 | -2.69 % | $ 4.13 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |